MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

Home・Elenco Azioni・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Chiusa

SettoreSettore sanitario

21.47

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

21.46

Massimo

21.48

Metriche Chiave
By Trading Economics
Entrata	-1.6M -21M
Vendite	14M 54M
Margine di Profitto	-39.611
Dipendenti	178
EBITDA	-3.8M -23M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	-2.84% downside

Dividendi
By Dow Jones
Utili prossimi	5 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	1B 2.2B
Apertura precedente	21.47
Chiusura precedente	21.47

Notizie sul Sentiment di mercato

By Acuity

50%

154 / 348 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

6.26 / 7.47 Supporto e resistenza

Day One Biopharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 apr 2026, 23:25 UTC

Principali Notizie su Eventi

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13 apr 2026, 22:45 UTC

Principali Notizie su Eventi

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13 apr 2026, 18:03 UTC

Utili

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13 apr 2026, 23:58 UTC

Utili

Review & Preview: Earnings Time -- Barrons.com

13 apr 2026, 23:49 UTC

Discorsi di Mercato

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13 apr 2026, 23:33 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13 apr 2026, 23:20 UTC

Discorsi di Mercato

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13 apr 2026, 23:01 UTC

Utili

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13 apr 2026, 23:01 UTC

Utili

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13 apr 2026, 23:01 UTC

Utili

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13 apr 2026, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13 apr 2026, 21:53 UTC

Utili

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13 apr 2026, 21:53 UTC

Utili

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13 apr 2026, 21:53 UTC

Utili

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13 apr 2026, 21:53 UTC

Utili

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13 apr 2026, 21:26 UTC

Principali Notizie su Eventi

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13 apr 2026, 21:23 UTC

Utili

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13 apr 2026, 21:16 UTC

Utili

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13 apr 2026, 20:50 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Basic Materials Roundup: Market Talk

13 apr 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

13 apr 2026, 20:34 UTC

Utili

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13 apr 2026, 20:34 UTC

Utili

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13 apr 2026, 20:34 UTC

Utili

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13 apr 2026, 19:59 UTC

Discorsi di Mercato

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13 apr 2026, 19:50 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13 apr 2026, 19:27 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Correction to Precious Metals Market Talk on April 9

13 apr 2026, 19:14 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13 apr 2026, 18:59 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13 apr 2026, 18:59 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13 apr 2026, 18:43 UTC

Discorsi di Mercato

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Confronto tra pari

Modifica del prezzo

Day One Biopharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

-2.84% in calo

Previsioni per 12 mesi

Media 20.86 USD -2.84%

Alto 21.5 USD

Basso 17 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Day One Biopharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Day One Biopharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

6.26 / 7.47Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

154 / 348 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.